The European Medicines Evaluations Agency on Monday announced that its scientific committee has rejected an application by Serono to market its anti-wasting drug Serostim to AIDS patients in Europe. The drug is approved for the treatment of AIDS-related wasting in the United States. In a statement, the agency said there was concern about the long-term safety of the medication and that long-term efficacy data also was lacking. Serostim is a recombinant human growth hormone that has been shown to increase muscle mass in those taking the medication.
Be sure to follow Advocate on your favorite social platform
DON'T MISS THE OUT100 SPECIAL 3 DAY MARATHON STARTING NOVEMBER 24TH!
Journey through the year’s influential Out100 – the most iconic and long-standing celebration of LGBTQ+ icons and allies – in a 1-hour television special spotlighting the LGBTQ+ people shaping the world today.